Attached files
file | filename |
---|---|
EX-4.4 - EX-4.4 DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE SECURITIES E - Apellis Pharmaceuticals, Inc. | apls-ex44_92.htm |
EX-32.2 - EX-32.2 - Apellis Pharmaceuticals, Inc. | apls-ex322_6.htm |
EX-32.1 - EX-32.1 - Apellis Pharmaceuticals, Inc. | apls-ex321_8.htm |
EX-31.2 - EX-31.2 - Apellis Pharmaceuticals, Inc. | apls-ex312_11.htm |
EX-31.1 - EX-31.1 - Apellis Pharmaceuticals, Inc. | apls-ex311_7.htm |
EX-23.1 - EX-23.1 - Apellis Pharmaceuticals, Inc. | apls-ex231_10.htm |
EX-21.1 - EX-21.1 - Apellis Pharmaceuticals, Inc. | apls-ex211_9.htm |
10-K - 10-K - Apellis Pharmaceuticals, Inc. | apls-10k_20191231.htm |
Exhibit 23.2
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
|
(1) |
Registration Statement (Form S-3 No. 333-235830) of Apellis Pharmaceuticals, Inc., and |
|
(2) |
Registration Statement (Form S-3 No. 333-229091) of Apellis Pharmaceuticals, Inc., and |
|
(3) |
Registration Statement (Form S-8 No. 333-229876) pertaining to the 2017 Stock Incentive Plan, Inducement Stock Option Award, and 2017 Employee Stock Purchase Plan of Apellis Pharmaceuticals, Inc., and |
|
(4) |
Registration Statement (Form S-8 No. 333-221528) pertaining to the 2010 Equity Incentive Plan, 2017 Stock Incentive Plan, and 2017 Employee Stock Purchase Plan of Apellis Pharmaceuticals, Inc.; |
of our report dated February 26, 2019, with respect to the consolidated financial statements of Apellis Pharmaceuticals, Inc. included in this Annual Report (Form 10-K) of Apellis Pharmaceuticals, Inc. for the year ended December 31, 2019.
/s/ Ernst & Young LLP
Boston, Massachusetts
February 27, 2020